Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8246813 | 1.00 | GAA (0.41) | GAANPSR1POLBCYP3A4CYP1A2 | |
| SCHEMBL13198671 | 1.00 | GAA (0.41) | GAANPSR1POLBCYP3A4CYP1A2 | |
| SCHEMBL418070 | 1.00 | GAA (0.41) | GAANPSR1POLBCYP3A4CYP1A2 | |
| SCHEMBL418068 | 1.00 | GAA (0.41) | GAANPSR1POLBCYP3A4CYP1A2 | |
| SCHEMBL3739039 | 0.91 | ALDH1A1 (0.49) | GAANPSR1POLBTSHRHSD17B10 | |
| SCHEMBL5823247 | 0.91 | ALDH1A1 (0.49) | GAANPSR1POLBTSHRHSD17B10 | |
| SCHEMBL417370 | 0.91 | ALDH1A1 (0.49) | GAANPSR1POLBTSHRHSD17B10 | |
| SCHEMBL5768836 | 0.91 | ALDH1A1 (0.49) | GAANPSR1POLBTSHRHSD17B10 | |
| SCHEMBL418463 | 0.91 | ALDH1A1 (0.49) | GAANPSR1POLBTSHRHSD17B10 | |
| SCHEMBL19730192 | 0.91 | ALDH1A1 (0.49) | GAANPSR1POLBTSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2547645-B1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | JANSSEN PHARMACEUTICALS INC (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3239129-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2017-06-01 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-9586893-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals (US) | 2017-03-07 | — | — | US | disclosed |
| US-9227965-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-9227965-B2 | Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-14 | — | — | US | disclosed |
| WO-2013041655-A1 | PROCESSES AND INTERMEDIATES FOR PREPARING A MACROCYCLIC PROTEASE INHIBITOR OF HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-03-28 | — | — | WO | disclosed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | disclosed |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2013-01-03 | — | — | US | disclosed |
| US-5374625-A | Bis/hydroxymethyl/cycloalkyl derivatives; viricides | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1994-12-20 | — | — | US | disclosed |
| EP-0468352-A2 | Novel nucleic acid derivatives | Nippon Kayaku Kabushiki Kaisha (JP) | 1992-01-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228574-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CPN1, CMA1, CYP51A1 | GAA 177/4885NPSR1 1358/4885POLB 1016/4885 |
| US-20170152253-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | GAA 586/4885NPSR1 251/4885POLB 1852/4885 |
| US-20130005976-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | HAVCR2, RNASE1, CPB1 | GAA 586/4885NPSR1 251/4885POLB 1852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.